ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

huperzine A

Also written as “Huperzine A injection”, “Huperzine A Oral Solution” and “Huperzine A for Injection”.

Its studies are mostly in Brain Injuries · Sensation Disorders · Schizophrenia · Alzheimer Disease, led by 5 companies.

Drug pageHuperzine A: every studyMany companies study it; this page follows only the 7 they lead. All 13 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 30, 20247 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Wanbangde Pharmaceutical Groupits history only32 open or runningphase 4since Apr 30, 2024Apr 27, 2024Dec 31, 2026phase 1 · NCT07784335
Biomedisynits history only10 open or runningphase 2since Aug 10, 2009Aug 10, 2009none ahead
Jiangsu Famous Medical Technology10 open or runningphase 4since Jul 22, 2020Jul 22, 2020none ahead
Luye Pharma Groupits history only10 open or runningphase 3since Jan 24, 2011Jan 24, 2011none ahead
Supernus Pharmaceuticalsits history only10 open or runningphase 1since May 15, 2017May 15, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jiangsu Famous Medical Technology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 22, 2020First study: phase 4 study in Sensation DisordersFirst studyNCT04509323 · 20 enrolled · China

TargetBeta

ACHE →read by rule
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule

Other programs on ACHE

ProgramCompanyFurthest phaseStudies
DonepezilruleEisaiphase 483
benzgalantamine gluconaterulealpha-cognition-incphase 41
Z 338ruleZeria Pharmaceuticalphase 312

Studies

The one study Jiangsu Famous Medical Technology leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04509323Sensation Disorders · China4UNKNOWNFeb 28, 202120

How it is read

Names in the registry

  • “Huperzine A injection”, 3 entries
  • “Huperzine A Oral Solution”, 1 entry
  • “Huperzine A for Injection”, 1 entry
  • “BIS-001 ER”, 1 entry
  • “huperzine 0.2 mg BID”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.